In addition, the significant therapeutic effect of cabozantinib, which targets MET, VEGFR2, and AXL, for bone metastasis in patients with RCC, prostate cancer, and breast cancer also indicates the importance of MET inhibition in the treatment of bone metastasis [10,22,23]. The gene discussed is KDR; the disease is prostate cancer.